← back to search

Tingting Zhang

Nantong University · CN
Area of research
Pharmacology · Global and Planetary Change
Research interest
Research interests include Temozolomide, Chemoradiotherapy, Glioblastoma, CD8, Refractory (planetary science), and Cancer research.
h-index
citations
97
works
9
NIH funding
primary concept
email

Recent publications

Targeting the IRE1α-XBP1s axis confers selective vulnerability in hepatocellular carcinoma with activated Wnt signaling
Oncogene 2024cited by 13position: firstdoi
Additional file 7 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 8 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 4 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 6 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 3 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 5 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
Additional file 1 of Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity
Figshare 2023cited by 0position: middledoi
MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
EMBO Molecular Medicine 2020cited by 84position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Ximiao He · Center for Cancer Research7 papers (2023–2023)Xiaohong Xu · National University of Singapore7 papers (2023–2023)Panpan Gao · Huazhong University of Science and Technology7 papers (2023–2023)Cheng Miao · Huazhong University of Science and Technology7 papers (2023–2023)Xiaoqian Chen · Ministry of Education of the People's Republic of China7 papers (2023–2023)Jiaxing Wu · Shihezi University7 papers (2023–2023)Qian Zhou · Kunming University of Science and Technology7 papers (2023–2023)Jingyi Peng · South China Agricultural University7 papers (2023–2023)Haifeng Jiang · Ministry of Education of the People's Republic of China7 papers (2023–2023)Xuan Cao · Huazhong University of Science and Technology7 papers (2023–2023)Feng Liu · Zhejiang University6 papers (2023–2023)Song-lin Yin · Huazhong University of Science and Technology6 papers (2023–2023)Xu Shijie · Guangzhou University of Chinese Medicine6 papers (2023–2023)Feng Pan · Fudan University4 papers (2023–2023) · 3 papers (2023–2023)Yang Jin · Shanghai University2 papers (2020–2024)Ningning Li · Sun Yat-sen University2 papers (2020–2024)Xia Sheng · Minhang District Central Hospital2 papers (2020–2024)Fengzhen Cui · Huazhong University of Science and Technology1 papers (2024–2024)Rong Zhong · Shuguang Hospital1 papers (2024–2024)